Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.30 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20972320 | 0.80 | TSHR (0.43) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL20972321 | 0.80 | TSHR (0.43) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL28957046 | 0.78 | HCAR2 (0.43) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL10314120 | 0.77 | TSHR (0.37) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL10314122 | 0.76 | TSHR (0.36) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL30573445 | 0.75 | — | — | |
| SCHEMBL615765 | 0.75 | — | — | |
| SCHEMBL21107707 | 0.74 | TSHR (0.39) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL29220266 | 0.74 | TSHR (0.39) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL19157088 | 0.74 | TSHR (0.39) | TSHRHCAR2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745375-B2 | Adipate-type compounds and a process of preparing it | HALDOR TOPSØE A/S (DK) | 2020-08-18 | — | — | US | disclosed |
| US-20200115359-A1 | NEW ADIPATE-TYPE COMPOUNDS AND A PROCESS OF PREPARING IT | HALDOR TOPSØE A/S (DK) | 2020-04-16 | — | — | US | disclosed |
| CN-109912416-A | The method that catalytic oxidation prepares glufosinate-ammonium and L- phosphine oxamate key intermediate | 洪湖市一泰科技有限公司 | 2019-06-21 | — | — | CN | disclosed |
| US-20190144415-A1 | NEW ADIPATE-TYPE COMPOUNDS AND A PROCESS OF PREPARING IT | HALDOR TOPSØE A/S (DK) | 2019-05-16 | — | — | US | disclosed |
| EP-3452459-A1 | NEW ADIPATE-TYPE COMPOUNDS AND A PROCESS OF PREPARING IT | Haldor Topsøe A/S (DK) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017191282-A1 | NEW ADIPATE-TYPE COMPOUNDS AND A PROCESS OF PREPARING IT | HALDOR TOPSØE A/S (DK) | 2017-11-09 | — | — | WO | disclosed |
| CN-101898955-B | Zeolite-catalyzed preparation of alpha-hydroxy carboxylic acid compounds and esters thereof | HALDOR TOPSOE AS | 2014-07-16 | — | — | CN | disclosed |
| EP-2184270-B1 | Zeolite-catalyzed preparation of alpha-hydroxy carboxylic acid compounds and esters thereof | HALDOR TOPSOE AS (DK) | 2013-02-13 | — | — | EP | disclosed |
| US-8143439-B2 | Zeolite-catalyzed preparation of alpha-hydroxy carboxylic acids and esters thereof | HALDOR TOPSØE A/S (DK) | 2012-03-27 | — | — | US | disclosed |
| CN-101898955-A | Zeolite-catalyzed preparation of alpha-hydroxy carboxylic acid compounds and esters thereof | HALDOR TOPSOE AS | 2010-12-01 | — | — | CN | disclosed |
| US-20100121096-A1 | ZEOLITE-CATALYZED PREPARATION OF ALPHA-HYDROXY CARBOXYLIC ACIDS AND ESTERS THEREOF | TOPSOE A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| EP-2184270-A1 | Zeolite-catalyzed preparation of alpha-hydroxy carboxylic acid compounds and esters thereof | Haldor Topsoe A/S (DK) | 2010-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144415-A1 | NEW ADIPATE-TYPE COMPOUNDS AND A PROCESS OF PREPARING IT | ADIPOR1, FABP4, ADIPOR2 | TSHR 4531/4885HCAR2 524/4885CA12 4234/4885 |
| US-10745375-B2 | Adipate-type compounds and a process of preparing it | ADIPOR1, FABP4, ADIPOR2 | TSHR 4519/4885HCAR2 566/4885CA12 4714/4885 |
| US-20100121096-A1 | ZEOLITE-CATALYZED PREPARATION OF ALPHA-HYDROXY CARBOXYLIC ACIDS AND ESTERS THEREOF | LDHA, HAO2, ALDOA | TSHR 3225/4885HCAR2 41/4885CA12 125/4885 |
| US-20200115359-A1 | NEW ADIPATE-TYPE COMPOUNDS AND A PROCESS OF PREPARING IT | ADIPOR1, FABP4, ADIPOR2 | TSHR 4498/4885HCAR2 616/4885CA12 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.